

“Regulatory Perspective”

(about this meeting)

Jeff Murray MD, MPH
Division of Antiviral Products
FDA

The Race of DAA Development




Recent Milestones

- AASLD Meeting 2010
- HCV DRAG meeting following AASLD
- Presentation of phase 3 results for two HCV protease inhibitors
- Presentation of results from combination DAAs without interferon
- FDA release of Draft Guidance 9/14/10
 - public comments posted 11/18/10

Guidance

What it is...



What it ain't...



